MitoRubion® Awarded at 2025 CAMPFIRE Crowdfunding Awards for Anti-Aging Supplement

Tackling Aging: MitoGenic's MitoRubion® Awarded at 2025 CAMPFIRE Crowdfunding Awards

The Japanese venture MitoGenic, based in Shinjuku, Tokyo, has recently gained recognition for its innovative supplement, MitoRubion®, at the prestigious 2025 CAMPFIRE Crowdfunding Awards. This annual event, organized by Japan's largest crowdfunding platform, CAMPFIRE, celebrates remarkable projects that contribute positively to society. MitoGenic received the Future Creation Award in the Best Project/Product-Tech category for its groundbreaking work in mitochondrial research and its applicability in anti-aging treatments.

Understanding MitoRubion®

MitoRubion® is a supplement derived from years of in-depth research on mitochondria conducted at Gakushuin University. The product harnesses a newly discovered plant-based compound named MitoRubion, aimed at enhancing mitochondrial function and combating the effects of aging. The recognition received by MitoGenic is a testament to the social relevance and future potential of their scientific endeavor, highlighting the importance of effective research in improving health and well-being.

The ambitious project was fully funded, raising an impressive 14,190,700 yen through 677 backers during its crowdfunding phase from February 7 to March 31, 2025. Supporters received early access to the supplement, along with additional products like MitoRubion bath salts and exclusive pamphlets that showcased the latest findings from mitochondrial research.

Looking Ahead: Expansion Plans

MitoGenic aims to broaden its commitment to health and aging care by evolving from dietary supplements and bath products to a diverse range of applications across food and beverage industries, cosmetics, pharmaceuticals, and even pet care. The company's ongoing research endeavors underscore a significant understanding of the benefits surrounding mitochondrial activity, reflecting a robust path toward innovation in health solutions.

Currently, MitoGenic is running a crowdfunding campaign for their new product aimed at supporting reproductive health, called MitoRubion Supplement with Folic Acid and Zinc. This latest initiative, scheduled from November 14, 2025, to January 27, 2026, focuses on key nutrients that support healthy conception, further exemplifying the company's commitment to addressing the health needs of its consumers.

A Message from the CEO

Keito Taniwaka, CEO of MitoGenic, expresses enthusiasm about the company's journey. He states, "We established MitoGenic to commercialize the groundbreaking plant-based ingredient MitoRubion derived from the university's research. The recognition from the CAMPFIRE Crowdfunding Awards is not just an acknowledgment of our research outcomes but also the collaborative effort with our supporters in product development. The decline in mitochondrial function is known to correlate with aging and various health conditions. We aspire to contribute to society by introducing innovative products and technologies that stem from our continual research."

About CAMPFIRE and the Award

The CAMPFIRE Crowdfunding Awards were initiated in 2017 to honor outstanding crowdfunding projects that stimulate innovation and foster community engagement. Celebrating its ninth installment this year, the awards highlight the immense potential of crowdfunding to bring creative ideas to fruition while creating meaningful impacts in society. MitoGenic's project was recognized for its success in translating research into practical applications, demonstrating co-creation with supporters, and showcasing strong future growth prospects.

MitoGenic's Commitment to Health

MitoGenic continues its mission to bridge the gap between academic research and societal needs, delivering the value of scientific advances to the public. The firm remains dedicated to sustainable health innovations, focusing on creating lasting health benefits through its acclaimed mitochondrial research.

For more details, visit the MitoRubion® Official Brand Site or contact MitoGenic for inquiries.